Although we cannot explain how different TMEM106B genotypes result in such clinical heterogeneity in our ALS cohort, the characterization of disease subgroups with different phenotypic traits is a crucial requirement to develop targeted therapies and to guide patients’ enrollment in clinical trials. The gene discussed is TMEM106B; the disease is amyotrophic lateral sclerosis.